The DOI matches its Crossref record; 85 of the 87 references it cites were found in a registry or an index, and 1 are not checked yet.
Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review
Open accessAbstract
Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, many breast cancer survivors either fail to take the correct dosage at the prescribed frequency (adherence) or discontinue therapy (persistence). This systematic review aims to: (1) determine the prevalence of adherence and persistence to adjuvant hormonal therapy among breast cancer survivors in clinical practice, and (2) identify correlates of adherence and persistence. We searched Medline, PubMed, PsycINFO, and CINAHL for studies that measured rates and/or correlates of adherence and/or persistence to adjuvant hormonal therapy. Studies were reviewed in a multi-step process: (1) the lead author screened titles and abstracts of all potentially eligible studies; (2) each coauthor reviewed a random 5 % sample of abstracts; and (3) two sets of coauthors each reviewed half of all “maybe” abstracts. Any disagreements were discussed until consensus was reached. Twenty-nine studies met inclusion criteria. Prevalence of adherence ranged from 41 to 72 % and discontinuation (i.e., nonpersistence) ranged from 31 to 73 %, measured at the end of 5 years of treatment. Extremes of age (older or younger), increasing out-of-pocket costs, follow-up care with a general practitioner (vs. oncologist), higher CYP2D6 activity, switching from one form of therapy to another, and treatment side effects were negatively associated with adherence and/or persistence. Taking more medications at baseline, referral to an oncologist, and earlier year at diagnosis were positively associated with adherence and/or persistence. Adherence and persistence to adjuvant hormonal therapy among breast cancer survivors is suboptimal. Many of the correlates of adherence and persistence studied to date are not modifiable. Our review reveals a critical need for further research on modifiable factors associated with adherence to adjuvant hormonal therapy, and the development of behavioral interventions to improve adherence in this population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“A meta-analysis reported 31%–73% of breast cancer survivors are adherent to AET,10”
From Refining and optimising a behavioural intervention to support endocrine therapy adherence (ROSETA) in UK women with breast cancer: Protocol for a pilot fractional factorial trial (2023) · cites this paper as [10]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, non-adherence is common with up to three-quarters of women prescribed adjuvant endocrine therapy (HT) taking < 80% of prescribed therapy and similar proportions discontinuing prematurely [4].”
From Acceptance and Commitment Therapy to support medication decision-making and quality of life in women with breast cancer: protocol for a pilot randomised controlled trial (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of barriers to medication use have been reported in this setting, including medication side-effects, psychological distress and a lack of social support [4, 15].”
From Acceptance and Commitment Therapy to support medication decision-making and quality of life in women with breast cancer: protocol for a pilot randomised controlled trial (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Non -adherence to adjuvant endocrine therapy (AET) in women with breast cancer is common and associated with medication side -effects and distress.”
The cited source says what the claim attributes to it.
In the citing paper
“Adherence to adjuvant endocrine therapy is affected by medication side-effects and associated distress.”
The cited source says what the claim attributes to it.
In the citing paper
“However, non-adherence is common with up to three-quarters of women prescribed adjuvant endocrine therapy (HT) taking < 80% of prescribed therapy and similar proportions discontinuing prematurely [4].”
The cited source says what the claim attributes to it.
In the citing paper
“Non-adherence to AET is a major problem among women with breast cancer [4]”
In the citing paper
“Despite these benefits, between 31-73% of survivors discontinue adjuvant hormonal therapy in clinical practice,6 thereby reducing treatment efficacy.7-10”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“However, few interventions have been developed to improve adjuvant hormonal therapy adherence.6”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“Patient variables (e.g., age), social support, patient-provider communication, and healthcare factors (e.g., cost) have been associated with breast cancer survivor adherence to systemic therapies.6, 16-18”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“However, adherence to hormonal therapy is suboptimal.”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“While hormonal treatment related side effects such as hot flashes and osteoporosis42 represent one of the main reasons for discontinuation,6 none of the retrieved interventions had an explicit focus on side effects.”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“Although studies have shown that adherence is problematic in both older and younger women similarly,6 the reasons for discontinuation or barriers to adherence may be different between the two groups.”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.006 · Cited by 10,578
Tamoxifen for early breast cancer: an overview of the randomised trials
Abe, O., Bartholomeus, S., & Piccart, M. J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,180
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
From Cancer Patient to Cancer Survivor: Lost in Transition
(2005) · PsycEXTRA Dataset · doi:10.1037/e720092007-001 · Cited by 2,364
Howell, A., Cuzick, J. M., Baum, M., Buzdar, A. U., Dowsett, M., Forbes, J., Hoctin-Boes, G., Houghton, J., Locker, G. Y., & Tobias, J. S. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17666-6 · Cited by 2,284
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70257-6 · Cited by 1,674
Williams, N. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70385-6 · Cited by 918
Howell, A. (1998) · PubMed · Cited by 901
Hershman, D. L., Shao, T., Kushi, L. H., Buono, D., Tsai, W. Y., Fehrenbacher, L., Kwan, M., Gomez, S. L., & Neugut, A. I. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1132-4 · Cited by 870
Fisher, B., Dignam, J. J., Bryant, J., DeCillis, A. P., Wickerham, D. L., Wolmark, N., Costantino, J. P., Redmond, C. K., Fisher, E. R., Bowman, D. M., et al. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.21.1529 · Cited by 857
Hershman, D. L., Kushi, L. H., Shao, T. H., Buono, D. L., Kershenbaum, A., Tsai, W., Fehrenbacher, L., Gomez, S. L., Miles, S. Q., & Neugut, A. I. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9655 · Cited by 834
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
Partridge, A. H., Wang, P. S., Winer, E. P., & Avorn, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.071 · Cited by 676
A Checklist for Medication Compliance and Persistence Studies Using Retrospective Databases
Peterson, A. M., Nau, D. P., Cramer, J. A., Benner, J., Gwadry-Sridhar, F. H., & Nichol, M. B. (2006) · Value in Health · doi:10.1111/j.1524-4733.2006.00139.x · Cited by 638
Patient adherence and persistence with oral anticancer treatment
Ruddy, K., Mayer, E., & Partridge, A. (2009) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20004 · Cited by 569 · cited 1×
“Persistence was defined as the duration from initiation to discontinuation of therapy [21].”
Ganz, P. A., Kwan, L., Stanton, A. L., Krupnick, J. L., Rowland, J. H., Meyerowitz, B. E., Bower, J. E., & Belin, T. R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh060 · Cited by 505
Adherence to Initial Adjuvant Anastrozole Therapy Among Women With Early-Stage Breast Cancer
Partridge, A. H., LaFountain, A., Mayer, E. L., Taylor, B. S., Winer, E. P., & Asnis-Alibozek, A. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5451 · Cited by 489
Henry, N. L., Azzouz, F., Desta, Z., Li, L., Nguyen, A., Lemler, S. M., Hayden, J. A., Tarpinian, K., Yakim, E., Flockhart, D. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0261 · Cited by 388
Neugut, A. I., Subar, M., Wilde, E. T., Stratton, S., Brouse, C. H., Hillyer, G. C., Grann, V. R., & Hershman, D. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.3179 · Cited by 359
McCowan, C., Shearer, J., Donnan, P. T., Dewar, J. A., Crilly, M., Thompson, A. M., & Fahey, T. P. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604758 · Cited by 343
Adherence to tamoxifen over the five-year course
Lash, T. L., Fox, M. P., Westrup, J., Fink, A. K., & Silliman, R. A. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9193-0 · Cited by 321
Managing Menopausal Symptoms in Breast Cancer Survivors: Results of a Randomized Controlled Trial
Ganz, P. A. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.13.1054 · Cited by 312
Mann, E., Smith, M. J., Hellier, J., Balabanovic, J. A., Hamed, H., Grunfeld, E. A., & Hunter, M. S. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70364-3 · Cited by 307
Owusu, C., Buist, D. S. M., Field, T. S., Lash, T. L., Thwin, S. S., Geiger, A. M., Quinn, V. P., Frost, F. J., Prout, M. N., Yood, M. U., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.1022 · Cited by 304
Adjuvant Tamoxifen: Predictors of Use, Side Effects, and Discontinuation in Older Women
Demissie, S., Silliman, R. A., & Lash, T. L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.322 · Cited by 301
Cella, D., & Fallowfield, L. J. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9548-1 · Cited by 286
Fink, A. K., Gurwitz, J. H., Rakowski, W., Guadagnoli, E., & Silliman, R. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.064 · Cited by 282
Potosky, A. L., Han, P. K. J., Rowland, J. H., Klabunde, C. N., Smith, T. G., Aziz, N. M., Earle, C. C., Ayanian, J. Z., Ganz, P. A., & Stefanek, M. E. (2011) · Journal of General Internal Medicine · doi:10.1007/s11606-011-1808-4 · Cited by 279
Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer
Ziller, V., Kalder, M., Albert, U., Holzhauer, W., Ziller, M., Wagner, U. A. G., & Hadji, P. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn646 · Cited by 263
Adherence to endocrine therapy for breast cancer
Chlebowski, R. T., & Geller, M. L. (2006) · Oncology · doi:10.1159/000100444 · Cited by 251
Patient Centered Experiences in Breast Cancer: Predicting Long-Term Adherence to Tamoxifen Use
Kahn, K. L., Schneider, E. C., Malin, J. L., Adams, J. L., & Epstein, A. M. (2007) · Medical Care · doi:10.1097/01.mlr.0000257193.10760.7f · Cited by 245
Adherence beliefs among breast cancer patients taking tamoxifen
Grunfeld, E. A., Hunter, M. S., Sikka, P., & Mittal, S. (2004) · Patient Education and Counseling · doi:10.1016/j.pec.2004.10.005 · Cited by 245
Nedrow, A. R., Miller, J., Walker, M., Nygren, P., Huffman, L. H., & Nelson, H. D. (2006) · PubMed · doi:10.1001/archinte.166.14.1453 · Cited by 242
Henry, N. L., Giles, J. T., Ang, D. C., Mohan, M., Dadabhoy, D., Robarge, J., Hayden, J., Lemler, S. M., Shahverdi, K., Powers, P., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9774-6 · Cited by 236
Mishel, M. H., Germino, B. B., Gil, K. M., Belyea, M., LaNey, I. C., Stewart, J., Porter, L., & Clayton, M. (2005) · Psycho-Oncology · doi:10.1002/pon.909 · Cited by 219
Underwood, J. M., Townsend, J. S., Stewart, S. L., Buchannan, N., Ekwueme, D. U., Hawkins, N. A., Li, J., Peaker, B., Pollack, L. A., Richards, T. B., et al. (2012) · PubMed · Cited by 199
Adjuvant hormonal therapy use among insured, low-income women with breast cancer
Kimmick, G., Anderson, R., Camacho, F., Bhosle, M., Hwang, W., & Balkrishnan, R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.2419 · Cited by 198
Wu, X., Lund, M. J., Kimmick, G. G., Richardson, L. C., Sabatino, S. A., Chen, V. W., Fleming, S. T., Morris, C. R., Huang, B., Trentham‐Dietz, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.8399 · Cited by 189
Sedjo, R. L., & Devine, S. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0952-6 · Cited by 176
Dezentjé, V. O., van Blijderveen, N. J. C., Gelderblom, H., Putter, H., van Herk-Sukel, M. P. P., Casparie, M. K., Egberts, A. C. G., Nortier, J. W. R., & Guchelaar, H.-J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0894 · Cited by 163
Side effects of aromatase inhibitors versus tamoxifen: the patients’ perspective
Garreau, J. R., DelaMelena, T., Walts, D., Karamlou, K., & Johnson, N. (2006) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2006.06.018 · Cited by 158
Meneses, K., McNees, P., Loerzel, V. W., Su, X., Zhang, Y., & Hassey, L. A. (2007) · Oncology nursing forum · doi:10.1188/07.onf.1007-1016 · Cited by 147
Burstein, H. J., Griggs, J. J., Prestrud, A. A., & Temin, S. (2010) · Journal of Oncology Practice · doi:10.1200/jop.000082 · Cited by 143
Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy
Hadji, P. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.02.001 · Cited by 137
van Herk‐Sukel, M. P. P., van de Poll-Franse, L. V., Voogd, A. C., Nieuwenhuijzen, G. A. P., Coebergh, J. W. W., & Herings, R. M. C. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0724-3 · Cited by 136
Taking CHARGE: a self-management program for women following breast cancer treatment
Cimprich, B., Janz, N. K., Northouse, L., Wren, P. A., Given, B., & Given, C. W. (2005) · Psycho-Oncology · doi:10.1002/pon.891 · Cited by 134
Cluze, C., Rey, D., Huiart, L., BenDiane, M. K., Bouhnik, A. D., Berenger, C., Carrieri, M. P., & Giorgi, R. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr330 · Cited by 133
Wigertz, A., Ahlgren, J., Holmqvist, M., Fornander, T., Adolfsson, J., Lindman, H., Bergkvist, L., & Lambe, M. P. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-1961-4 · Cited by 123
Presant, C. A., Bosserman, L. D., Young, T., Vakil, M., Horns, R. C., Upadhyaya, G. H., Ebrahimi, B., Yeon, C. H., & Howard, F. (2007) · Clinical Breast Cancer · doi:10.3816/cbc.2007.n.038 · Cited by 122
Noncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patients
Ma, A. M. T., Barone, J., Wallis, A. E., Wu, N. J., Garcia, L. B., Estabrook, A., Rosenbaum-Smith, S. M., & Tartter, P. I. (2008) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2008.06.027 · Cited by 115
Fellowes, D., Fallowfield, L. J., Saunders, C. M., & Houghton, J. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1010684903199 · Cited by 100
Nekhlyudov, L., Li, L., Ross‐Degnan, D., & Wagner, A. K. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1703-z · Cited by 99
Huiart, L., Bouhnik, A.-D., Rey, D., Tarpin, C., Cluze, C., Bendiane, M. K., Viens, P., & Giorgi, R. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.03.004 · Cited by 97
Hunter, M. S., Coventry, S., Hamed, H., Fentiman, I. S., & Grunfeld, E. A. (2008) · Psycho-Oncology · doi:10.1002/pon.1414 · Cited by 94
Livaudais, J. C., Hershman, D. L., Habel, L., Kushi, L., Gomez, S. L., Li, C. I., Neugut, A. I., Fehrenbacher, L., Thompson, B., & Coronado, G. D. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1762-1 · Cited by 93
Thompson, A. M., Johnson, A., Quinlan, P., Hillman, G. R., Fontecha, M., Bray, S. E., Purdie, C. A., Jordan, L. B., Ferraldeschi, R., Latif, A., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1139-x · Cited by 87
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients
Rae, J. M., Sikora, M. J., Henry, N. L., Li, L., Kim, S., Oesterreich, S., Skaar, T. C., Nguyen, A., Desta, Z., Storniolo, A. M., et al. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.14 · Cited by 86
Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review
Banning, M. (2011) · European Journal of Cancer Care · doi:10.1111/j.1365-2354.2011.01295.x · Cited by 83
Predicting Adherence to Tamoxifen for Breast Cancer Adjuvant Therapy and Prevention
Lin, J., Zhang, S. M., & Manson, J. E. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0380 · Cited by 83
Management of menopausal symptoms in patients with breast cancer: an evidence-based approach
Hickey, M., Saunders, C. M., & Stuckey, B. G. A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70316-8 · Cited by 83
Pellegrini, I., Sarradon‐Eck, A., Soussan, P. B., Lacour, A., Largillier, R., Tallet, A. R., Tarpin, C., & Julian‐Reynier, C. (2009) · Psycho-Oncology · doi:10.1002/pon.1593 · Cited by 82
Weaver, K. E., Camacho, F., Hwang, W., Anderson, R. T., & Kimmick, G. G. (2012) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3182436ec1 · Cited by 73
Huiart, L., Dell’Aniello, S., & Suissa, S. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.140 · Cited by 71
Adherence to Oral Endocrine Therapy for Breast Cancer: A Nursing Perspective
Miaskowski, C. A., Shockney, L. D., & Chlebowski, R. T. (2008) · Clinical journal of oncology nursing · doi:10.1188/08.cjon.213-221 · Cited by 67
Adherence to long-term adjuvant hormonal therapy for breast cancer
Gotay, C. C., & Dunn, J. (2011) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.11.80 · Cited by 65
Neugut, A. I., Hillyer, G. C., Kushi, L. H., Lamerato, L., Leoce, N., Nathanson, S. D., Ambrosone, C. B., Bovbjerg, D. H., Mandelblatt, J. S., Magai, C., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2066-9 · Cited by 63
Riley, G. F., Warren, J. L., Harlan, L. C., & Blackwell, S. A. (2011) · Medicare & Medicaid Research Review · doi:10.5600/mmrr.001.04.a04 · Cited by 58
Güth, U., Huang, D. J., Schötzau, A., Zanetti‐Dällenbach, R., Holzgreve, W., Bitzer, J., & Wight, E. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604525 · Cited by 58
van de Water, W., Bastiaannet, E., Hille, E. T. M., Kranenbarg, E. M., Putter, H., Seynaeve, C., Paridaens, R., de Craen, A. J. M., Westendorp, R. G. J., Liefers, G., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0037 · Cited by 55
Güth, U., Myrick, M. E., Schötzau, A., Kilic, N., & Schmid, S. M. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1668-y · Cited by 51
Arthralgia During Aromatase Inhibitor Treatment in Early Breast Cancer Patients
Boonstra, A., van Zadelhoff, J., Timmer-Bonte, A., Ottevanger, P. B., Beurskens, C. H. G., & van Laarhoven, H. W. M. (2012) · Cancer Nursing · doi:10.1097/ncc.0b013e31824a7e18 · Cited by 45
Mann, E., Smith, M. J., Hellier, J. M., & Hunter, M. S. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-44 · Cited by 43
Managing the toxicities of the aromatase inhibitors
Mortimer, J. E. (2009) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e328334e44e · Cited by 36
Adherence to oral endocrine treatments in women with breast cancer: can it be improved?
Doggrell, S. A. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1578-z · Cited by 34
Menopausal-type symptoms among breast cancer patients on aromatase inhibitor therapy
Gallicchio, L. M., MacDonald, R., Wood, B., Rushovich, E., & Helzlsouer, K. J. (2011) · Climacteric · doi:10.3109/13697137.2011.620658 · Cited by 31
Albert, U., Zemlin, C., Hadji, P., Ziller, V., Kuhler, B., Frank-Hahn, B., Wagner, U. A. G., & Kalder, M. (2011) · Breast Care · doi:10.1159/000329006 · Cited by 30
Patient Adherence to Aromatase Inhibitor Treatment in the Adjuvant Setting
Verma, S., Madarnas, Y., Sehdev, S. R., Martin, G., & Bajcar, J. (2011) · Current Oncology · doi:10.3747/co.v18i0.899 · Cited by 27
Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer
Schwartzberg, L. S., Cobb, P. W., Senecal, F. M., Henry, D. W., Kulig, K., Walker, M. S., Houts, A. C., & Stepanski, E. J. (2009) · The Breast · doi:10.1016/j.breast.2009.01.002 · Cited by 17
Effectively nursing patients receiving aromatase inhibitor therapy
Wengström, Y. (2008) · The Breast · doi:10.1016/j.breast.2007.11.001 · Cited by 14
Compliance to adjuvant therapy in breast cancer patients.
Dittmer, C., Roeder, K., Hoellen, F., Salehin, D., Thill, M., & Fischer, D. (2011) · PubMed · Cited by 13
Rothman, K. J., Huybrechts, K. F., & Murray, E. J. (2024) · doi:10.1093/oso/9780197751541.001.0001 · Cited by 12
Improving adherence to endocrine therapies: the role of advanced practice nurses.
Kelly, A., & Agius, C. R. (2006) · PubMed · Cited by 11
Nonhormonal Therapies for Menopausal Hot Flashes: Systematic Review and Meta-analysis
Nelson, H. D., Vesco, K. K., Haney, E., Fu, R., Nedrow, A., Miller, J., Nicolaidis, C., Walker, M., & Humphrey, L. (2006) · JAMA · doi:10.1001/jama.295.17.2057 · Cited by 4
Research works printed but not linked: 1
- Salgado BA, Zivian MT (2006) Aromatase inhibitors: side effects reported by 622 women. Breast Cancer Res Treat 100:S1618
Cited by
Sorted by citations
Burstein, H. J., Temin, S., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. A., Giordano, S. H., Hudis, C. A., Rowden, D., Solky, A. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.2258 · Cited by 816
Biology of breast cancer in young women
Azim, H. A., & Partridge, A. H. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0427-5 · Cited by 475
Bodai, B. I., & Tuso, P. (2015) · The Permanente Journal · doi:10.7812/tpp/14-241 · Cited by 397
A Systematic Review of Adherence to Oral Antineoplastic Therapies
Greer, J. A., Amoyal, N. R., Nisotel, L. E., Fishbein, J. N., MacDonald, J. J., Stagl, J. M., Lennes, I. T., Temel, J. S., Safren, S. A., & Pirl, W. F. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0405 · Cited by 364
Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors
Irwin, M. L., Cartmel, B., Gross, C. P., Ercolano, E., Li, F., Yao, X., Fiellin, M., Capozza, S., Rothbard, M., Zhou, Y., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1547 · Cited by 324
Metadata
- Authors
- Murphy, C. C., Bartholomew, L. K., Carpentier, M. Y., Bluethmann, S. M., & Vernon, S. W.
- Affiliations
- The University of Texas Health Science Center at Houston (US)
- Corresponding author
- Murphy, Caitlin C.
- Venue
- Breast Cancer Research and Treatment
- Published
- 2012-06-12
- Volume
- 134
- Issue
- 2
- Pages
- 459-478
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- PMC
- PMC3607286
- OpenAlex
- W1987753117
- Semantic Scholar
- 92816b1cff05e88d3955bfa52d7d9c9f3eafb040
- Cited by
- 708
- References
- 85
- Citations by year
- 2026: 32 · 2025: 63 · 2024: 59 · 2023: 67 · 2022: 71 · 2021: 59 · 2020: 60 · 2019: 54 · 2018: 41 · 2017: 64 · 2016: 33 · 2015: 38 · 2014: 32 · 2013: 34 · 2012: 1
- FWCI
- 4.41
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Breast Cancer Research and Treatment (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (R25CA057712, R01CA112223, K07CA140159)
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- adjuvant endocrine therapy, breast cancer survivors, medication adherence, treatment persistence, tamoxifen, aromatase inhibitors, hormone receptor-positive breast cancer, out-of-pocket costs, treatment side effects, behavioral interventions
- MeSH terms
- Breast Neoplasms, Clinical Trials as Topic, Female, Humans, Neoplasms, Hormone-Dependent, Chemotherapy, Adjuvant, Survivors, Antineoplastic Agents, Hormonal, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
